1. Search Result
Search Result
Results for "

OCA

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Recombinant Proteins

6

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0607
    Nitisinone
    2 Publications Verification

    NTBC; Nitisone; SC0735

    HPPD Metabolic Disease
    Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism .
    Nitisinone
  • HY-153114

    FXR Inflammation/Immunology
    HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
    HEC96719
  • HY-RS09739

    Small Interfering RNA (siRNA) Others

    OCA2 Human Pre-designed siRNA Set A contains three designed siRNAs for OCA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    OCA2 Human Pre-designed siRNA Set A
    OCA2 Human Pre-designed siRNA Set A
  • HY-139636

    TGF-β Receptor Others
    MCA17-1 shows stronger bioactivity than the positive control obeticholic acid (OCA) against liver fibrosis.
    MCA17-1
  • HY-169792

    FXR Aminotransferases (Transaminases) Metabolic Disease Inflammation/Immunology
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .
    HPG1860
  • HY-W414824

    Endogenous Metabolite Neurological Disease
    3β,7β-Dihydroxy-5-cholestenoic acid is a C27 acid that displays elevated levels in Niemann-Pick type C and Niemann-Pick type B diseases, contributing to toxicity in oculomotor neurons. It is synthesized from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) through the enzymatic action of hydroxysteroid 11-β dehydrogenase 1.
    3β,7β-Dihydroxy-5-cholestenoic acid
  • HY-B0607R

    NTBC (Standard); Nitisone (Standard); SC0735 (Standard)

    HPPD Reference Standards Metabolic Disease
    Nitisinone (Standard) is the analytical standard of Nitisinone. This product is intended for research and analytical applications. Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism .
    Nitisinone (Standard)
  • HY-151959

    FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: